Last quarter (Q ), XBiotech's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q, XBiotech's net income was $-4.63M. See XBiotech’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	$ 4.01M	$ 18.39M	$ 44.00M	$ 0.00
Cost of Revenue	-	-	$ 651.00K	$ -5.82M	$ 34.55M	$ 0.00
Gross Profit	-	-	$ 3.36M	$ 12.57M	$ 9.45M	$ 0.00
Operating Expense	$ 23.22M	$ 37.51M	$ 37.85M	$ -37.66M	$ 27.73M	$ 31.23M
Operating Income	$ -23.22M	$ -37.51M	$ -34.49M	$ -43.48M	$ -18.28M	$ -31.23M
Net Non Operating Interest Income Expense	$ 5.29M	-	-	$ 467.00K	$ 2.46M	$ 564.00K
Other Income Expense	$ -6.02M	$ -11.30M	$ -3.70M	$ -18.26M	$ 2.99M	$ 749.12M
Pretax Income	$ -24.31M	$ -24.31M	$ -33.59M	$ -25.46M	$ -12.83M	$ 718.45M
Tax Provision	$ 318.00K	$ 244.00K	$ -688.00K	$ -8.04M	$ -1.61M	$ 49.82M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -10.34M	$ -24.56M	$ -32.90M	$ -17.41M	$ -11.22M	$ 668.63M
Basic EPS	$ -0.81	$ -0.81	$ -1.08	$ -0.58	$ -0.36	$ 17.17
Diluted EPS	$ -0.81	$ -0.81	$ -1.08	$ -0.58	$ -0.36	$ 14.44
Basic Average Shares	$ 121.75M	$ 30.44M	$ 30.44M	$ 30.04M	$ 30.82M	$ 38.95M
Diluted Average Shares	$ 121.75M	$ 30.44M	$ 30.44M	$ 30.04M	$ 30.82M	$ 46.32M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 23.22M	$ 37.51M	$ 38.50M	$ -43.48M	$ 62.27M	$ 31.23M
Net Income From Continuing And Discontinued Operation	$ -24.56M	$ -24.56M	$ -32.90M	$ -17.41M	$ -11.22M	$ 668.63M
Normalized Income	$ -17.26M	$ -19.21M	$ -34.28M	-	$ -14.28M	$ 669.46M
Interest Expense	-	-	-	-	-	-
EBIT	$ -27.09M	$ -24.31M	$ -33.59M	$ -25.93M	$ -18.28M	$ -31.23M
EBITDA	$ -18.72M	$ -22.57M	$ -30.97M	$ -23.28M	$ -16.04M	$ -28.87M

Currency in USD

XBiotech Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing